Tetra Pharm Technologies Advances CB1 Antagonist TPT0701 for Appetite Suppression into Preclinical Testing
Tetra Pharm Technologies announces the advancement of TPT0701, a novel appetite suppressant targeting the endocannabinoid system, offering innovative solutions for combating obesity.
Following the successful filing of the Intellectual Property (IP) for its applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies is moving forward with its appetite suppression supplement, TPT0701.
Modulation of the endocannabinoid system has long been recognized as a promising way to regulate appetite. Through intensive research and development, Tetra Pharm Technologies has unlocked the potential of this biological system to address one of the most pressing health problems of our time – excessive appetite and weight gain.
TPT0701 was originally developed in 2022 for obese patients with schizophrenia, but is now set to enter development as an appetite suppressant for general weight loss.
Dr. Morten Allesø, Chief Scientific Officer, Tetra Pharm Technologies, said: “With our new, proprietary platform technology as our secret weapon to unlock the infinite possibilities of the endocannabinoid system, we are now ready to complete TPT0701 for preclinical testing in 2024.”
“Compounds such as TPT0701 have physicochemical properties that make them difficult to formulate using conventional methods. Our platform technology, now supported by an IP application, can accommodate exactly these types of molecules and will help overcome the problems of drug delivery, such as poor absorption and ultimately low bioavailability. A drug is only as good as its delivery system, and since both the formulation technology and the pharmacological mode of action have been demonstrated in the early stages of drug development, we are confident that TPT0701 will be successful as development progresses,” Morten Allesø added.
TPT0701 offers a novel approach to appetite suppression that aims to provide people with a safe and effective means to control their cravings and achieve their wellness goals. Because Tetra Pharm Technologies’ solution specifically targets the endocannabinoid system, it holds promise for combating obesity and related metabolic disorders, with far-reaching public health implications.
“Obesity and its associated health risks have reached alarming levels worldwide, so innovative approaches are needed to tackle this urgent problem. R&D is our top priority, and we will continue to invest in building our pipeline of new drug candidates targeting the endocannabinoid system and related diseases,” said Martin Rose, Managing Director, Tetra Pharm Technologies.
